Lakefront Appoints Big Pharma Vet to Steer Autoimmune Strategy

MECHELEN, Belgium – November 02, 2026 — In a move that underscores the rapidly blurring lines between oncology and immunology, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) has appointed Dr. Mehdi Shahidi as a Non-Executive Independent Director to its Board of Directors. Effective today, Dr. Shahidi succeeds Dr. Paulo Fontoura, who departed the board in July to become the Global Head of R&D at Sanofi SA.

The appointment is far more than a routine governance update. For Lakefront—a clinical-stage biotechnology company that recently rebranded from Galapagos NV to signal a hard pivot into immunology and inflammation—bringing Dr. Shahidi into the fold is a calculated strategic maneuver. It aligns the company's boardroom expertise directly with the complex clinical and financial demands of its lead asset, gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager (TCE) for autoimmune diseases.

“We are thrilled to welcome Mehdi to the Board. I’m confident his extensive experience in drug development, history of regulatory success, and track record of building organizations will strengthen the Board’s ability to provide strategic guidance to Lakefront as it continues to advance gamgertamig and its preclinical assets, while maintaining a disciplined approach to deploying its strategic capital,” said Gino Santini, Chair of the Board of Directors.

The Great Migration: Oncology Expertise Meets Autoimmunity

To understand the strategic weight of Dr. Shahidi's appointment, one must look at the broader macroeconomic and scientific shifts reshaping biopharma. Historically, T-cell engagers were the exclusive domain of oncology, specifically engineered to hunt down hematologic malignancies like multiple myeloma. Today, these same mechanisms are being repurposed to treat severe autoimmune diseases by depleting pathogenic B cells and plasma cells, effectively offering patients an "immune reset."

Dr. Shahidi’s background perfectly encapsulates this industry-wide migration. A clinical oncologist who trained at the Royal Marsden Hospital, he spent years as the Senior Vice President, Global Head of Medicine, and Chief Medical Officer at Boehringer Ingelheim. During his tenure, he oversaw a massive global organization, guiding diverse drug development programs through complex regulatory approvals.

"The next blockbuster autoimmune therapies are being built on the chassis of yesterday's oncology breakthroughs," noted one senior biopharma equity analyst. "Bringing a veteran oncologist with global regulatory experience onto an immunology-focused board is no longer a paradox; it is a strategic prerequisite."

By recruiting an executive who understands the intricate safety profiles, dosing regimens, and regulatory hurdles of T-cell engagers from their origins in cancer care, Lakefront is future-proofing its clinical strategy as it navigates uncharted territory in autoimmunity.

Steering Gamgertamig Through a Crowded Clinical Landscape

Lakefront’s immediate future hinges on gamgertamig (also known as OM336). The drug is a bispecific antibody designed to direct T cells toward BCMA-expressing cells that drive autoimmune diseases. Crucially, it is engineered with a "detuned" or reduced-affinity CD3-binding arm. This structural nuance is a strategic differentiator, designed to promote target-dependent activity and avoid the severe immune overactivation (such as cytokine release syndrome) that has historically plagued oncology TCEs, thereby widening the therapeutic index for autoimmune patients.

Gamgertamig is currently advancing through two critical global Phase 1b basket studies. The first (NCT07083960) targets autoimmune cytopenias like immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). The second (NCT07229144) focuses on seropositive autoimmune diseases, including idiopathic inflammatory myositis and Sjögren's disease.

The asset has already garnered significant regulatory momentum, securing Fast Track Designation for AIHA and ITP, as well as Orphan Drug Designations for AIHA, ITP, and, most recently in August 2026, pemphigus.

However, Lakefront is not advancing this asset in a vacuum. The company is developing gamgertamig in collaboration with Gilead Sciences, which acquired the drug's original developer, Ouro Medicines, in a deal valued at up to $2.175 billion. While Gilead retains global commercialization rights and will lead later-stage development, Lakefront is tasked with steering the critical early-stage clinical studies. Dr. Shahidi’s deep experience in translational research and early clinical development will be instrumental as Lakefront pushes to initiate additional proof-of-concept studies and registrational development by 2027.

Capital Discipline in a High-Stakes Market

Beyond clinical execution, Dr. Shahidi brings a critical venture capital and entrepreneurial lens to the boardroom. He currently serves as Head of Development and CMO at Ottimo Pharma, is a founder of Petalion Therapeutics, and, perhaps most notably for Lakefront's corporate strategy, acts as a Venture Partner at Medicxi, a premier European life sciences investment firm. He also brings valuable governance experience from his time on the Supervisory Board of the mRNA pioneer CureVac.

This dual perspective—clinical operator and venture capitalist—is vital for Lakefront. Following its transformation from Galapagos, the company sits on a formidable war chest. As of mid-2026, Lakefront reported over €135 million in cash and cash equivalents, alongside a staggering €2.1 billion in financial investments.

In the current biotech market, having capital is only half the battle; deploying it efficiently is what separates market leaders from acquisition targets. Lakefront has already demonstrated a commitment to active capital management, evidenced by a recent share repurchase program executed in August 2026. Dr. Shahidi’s venture capital background will help the board balance internal pipeline funding with aggressive, opportunistic M&A to acquire high-quality assets that complement gamgertamig.

A Strategic Blueprint for the Next Wave of Biopharma

The race to dominate the autoimmune T-cell engager market is intensifying. Competitors are moving rapidly; Otsuka and Harbour BioMed are advancing their own BCMAxCD3 TCE (HBM7020) into human testing for systemic lupus erythematosus and rheumatoid arthritis, while UCB recently licensed a CD19xCD3 bispecific from Antengene.

In this hyper-competitive environment, success requires more than just a promising molecule. It demands a corporate infrastructure capable of navigating complex clinical trials, managing multi-billion-dollar partnerships, and executing shrewd capital allocation.

By replacing a departing R&D executive with a seasoned oncologist-turned-venture-partner, Lakefront Biotherapeutics is not merely filling an empty seat. The company is actively redesigning its strategic brain trust. Dr. Shahidi’s appointment signals to investors and competitors alike that Lakefront understands the unique intersection of oncology mechanics and immunology markets, and is positioning itself to lead the next great frontier in biopharmaceutical innovation.